Literature DB >> 17409647

Clinical pharmacokinetics of oseltamivir and its active metabolite oseltamivir carboxylate after oral administration in horses.

Takashi Yamanaka1, Masayuki Yamada, Koji Tsujimura, Takashi Kondo, Shunichi Nagata, Seiji Hobo, Masahiko Kurosawa, Tomio Matsumura.   

Abstract

The aim of this study was to investigate the pharmacokinetics of oseltamivir carboxylate (OC) in horses (n=6) after oral administration of its prodrug oseltamivir. The binding rate of OC to horse plasma proteins was negligible (<1%). Oral administration of oseltamivir of 2 mg/kg body weight of oseltamivir to horses provided a plasma concentration of OC (mean maximum concentration: 257.9 ng/ml) above the inhibitory concentrations against equine influenza A viruses determined in vitro. However, because OC is rapidly eliminated from horse plasma (mean elimination half-life: 2.5 hr), administration intervals should be less than 10 hr to retain a suitable concentration when using a single dose of 2 mg/kg oseltamivir.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17409647     DOI: 10.1292/jvms.69.293

Source DB:  PubMed          Journal:  J Vet Med Sci        ISSN: 0916-7250            Impact factor:   1.267


  2 in total

1.  Generic approach for the discovery of drug metabolites in horses based on data-dependent acquisition by liquid chromatography high-resolution mass spectrometry and its applications to pharmacokinetic study of daprodustat.

Authors:  Hideaki Ishii; Mariko Shibuya; Kanichi Kusano; Yu Sone; Takahiro Kamiya; Ai Wakuno; Hideki Ito; Kenji Miyata; Fumio Sato; Taisuke Kuroda; Masayuki Yamada; Gary Ngai-Wa Leung
Journal:  Anal Bioanal Chem       Date:  2022-10-01       Impact factor: 4.478

2.  Quantitative trace analysis of a broad range of antiviral drugs in poultry muscle using column-switch liquid chromatography coupled to tandem mass spectrometry.

Authors:  Bjorn J A Berendsen; Robin S Wegh; Martien L Essers; Alida A M Stolker; Stefan Weigel
Journal:  Anal Bioanal Chem       Date:  2011-12-16       Impact factor: 4.142

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.